Catherine T. Doherty sold $5.4M of DGX
EVP, Regional Businesses at QUEST DIAGNOSTICS INC. 26,165 shares at an average of $206.15, traded Feb 13, 2026, filed Feb 17, 2026.
Score components
- +15RoleOfficer
- +25Trade size$5.4M at market
- +10Share of holdings soldSold 28% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -5.5%, 3m -6.9%, 6m +15.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001022079-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 13, 2026 | MOption exercise Common Stock10b5-1 | +26,165 | $112.17 | $2.9M | 94,233 | Feb 17, 2026 |
| Feb 13, 2026 | SOpen-market sale Common Stock10b5-1 | -10,573 | $205.21 | $2.2M | 83,660 | Feb 17, 2026 |
| Feb 13, 2026 | SOpen-market sale Common Stock10b5-1 | -10,122 | $206.37 | $2.1M | 73,538 | Feb 17, 2026 |
| Feb 13, 2026 | SOpen-market sale Common Stock10b5-1 | -3,500 | $207.08 | $725k | 70,038 | Feb 17, 2026 |
| Feb 13, 2026 | SOpen-market sale Common Stock10b5-1 | -1,619 | $208.21 | $337k | 68,419 | Feb 17, 2026 |
| Feb 13, 2026 | SOpen-market sale Common Stock10b5-1 | -351 | $209.10 | $73k | 68,068 | Feb 17, 2026 |
| Feb 13, 2026 | MOption exercise Non-Qualifed Stock Option (right to buy)derivative10b5-1 | -26,165 | $112.17 | $2.9M | 0 | Feb 17, 2026 |
Related signals
Other insiders at QUEST DIAGNOSTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | QUEST DIAGNOSTICS INC | J. E. Davis CEO and President | $2.4M 10,000 shares | -8% | |
| 23Weak | QUEST DIAGNOSTICS INC | Michael E Prevoznik SVP & General Counsel | $5.5M 22,677 shares | -38% | |
| 16Weak | QUEST DIAGNOSTICS INC | Mark E Delaney SVP & Chief Commercial Officer | $376k 1,600 shares | -13% | |
| 23Weak | QUEST DIAGNOSTICS INC | Karthik Kuppusamy SVP, Clinical Solutions | $1.6M 8,147 shares | -38% | |
| 38Weak | QUEST DIAGNOSTICS INC | J. E. Davis CEO and President | $1.9M 10,000 shares | -7% | |
| 35Weak | QUEST DIAGNOSTICS INC | Catherine T. Doherty EVP, Regional Businesses | $1.1M 5,558 shares | -8% | |
| 54Moderate | QUEST DIAGNOSTICS INC | Karthik Kuppusamy SVP, Clinical Solutions | $538k 2,628 shares | -16% | |
| 32Weak | QUEST DIAGNOSTICS INC | Michael E Prevoznik SVP & General Counsel | $800k 3,878 shares | -9% | |
| 34Weak | QUEST DIAGNOSTICS INC | Patrick Plewman SVP for Diagnostic Services | $589k 2,855 shares | -16% | |
| 45Moderate | QUEST DIAGNOSTICS INC | J. E. Davis CEO and President | $2.1M 10,000 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.